Rapports de cas cliniques et médicaux

One of the leading causes of misery and mortality worldwide, malignant growth poses a serious threat to human wellness and personal happiness. Due to their accessibility and lack of harmfulness, common food components stand out enough to be taken into account in the treatment and prevention of disease. Rosmarinic acid (RA) is renowned for its remarkable cell-reinforcing qualities and is safe and effective in preventing and obstructing malignancies. This audit compiles late distributions on extraction cycles, hostile growth uses, and culture procedures for RAadvanced dietary supplements. We look at ways to increase RA bioavailability and provide a thoughtless discussion of RA in relation to growth inhibition, treatment, and adjuvant therapy. Through controlling oxidative pressure, ongoing inflammation, cell cycle, death, and metastasis, RA exhibits anticancer activity. According to this knowledge, daily use of RA-improved dietary modifications can help with both growth anticipation and treatment. RA has the potential to be used in the development of anti-cancer drugs.

Objective: To evaluate the effect of the combination of inositolic derivatives and lipid mediators on the metabolic and inflammatory profile of women with polycystic ovary syndrome.

Material and methods: Experimental, prospective and longitudinal study carried out in patients diagnosed with polycystic ovary syndrome (Rotterdam criteria) without treatment or previous dietary intervention. The following nutritional preparations were administered orally daily: Group A: 300mg D-chiro-inositol, 1099mg myo- inositol + 30mg lipinova Group B: 4000 mg of myo-inositol + 30 mg of lipinova The metabolic profile is compared before and after 4 weeks of treatment in each patient, determining the insulin levels and the HOMA index. The inflammatory profile was analyzed by determining the levels of IL-6 before and after treatment.

Results: 41 patients with polycystic ovary syndrome subdivided into 20 from group A and 21 from group B were studied. Insulin levels before and after treatment was 17.9 ± 9.3 SD and 10 ± 4.09 SD, respectively, with statistically significant differences. The HOMA index pre-treatment was 4.1 ± 2.1 SD and 2.1 ± 1.1 SD post-treatment, with significant differences the level of IL-6 was pretreatment was 3.8 ± 1.5 Sd of 2.1 ± 1.09 post treatment with significant differences.

Conclusion: The results of the study show the positive effect of the combined administration of inositolic derivatives and pro-resolution lipid mediators on the metabolic, clinical and inflammatory profile of patients with polycystic ovary syndrome.